K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released November 13, 2003; last updated August 19, 2019; expires August 19, 2022

This article includes discussion of atomoxetine and Strattera. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.

Historical note and terminology

Most of the drugs for the treatment of attention-deficit/hyperactivity disorder (ADHD) have been CNS stimulants in the past. Originally called tomoxetine, the drug's name was changed to atomoxetine to avoid any potential confusion with the anticancer drug tamoxifen that might lead to dispensing errors. Atomoxetine is not a controlled substance in the United States. It is the first nonstimulant approved by the FDA for the treatment of ADHD in children, adolescents, and adults.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.